<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029350</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-03-II-01</org_study_id>
    <nct_id>NCT04029350</nct_id>
  </id_info>
  <brief_title>Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M</brief_title>
  <acronym>ALTN-03</acronym>
  <official_title>A Multi-center, One-arm, Phase II Trial of Anlotinib Combined With Osimertinib as the Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy and safety of Anlotinib combined with Icotinib as the second-line
      treatment in stage IIIb-IV NSCLC patients with sensitive EGFR and T790M mutations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anlotinib Hydrochloride is a kind of innovative medicines approved by State Food and Drug
      Administration（CFDA:2011L00661） which was developed by Jiangsu Chia-tai Tianqing
      Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with
      multi-targets, especially for VEGFR1、VEGFR2、VEGFR3、FGFR1/2/3、PDGFRa/β and c-Kit.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>each 42 days up to PD or death (up to 24 months)</time_frame>
    <description>The PFS time is defined as time from enrollment to locoregional or systemic recurrence, second malignancy or death due to any cause; censored observations will be the last date of : &quot;death&quot;, &quot;last tumor assessment&quot;, &quot;last follow up date&quot; or &quot;last date in drug log&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS（Overall Survival）</measure>
    <time_frame>up to 24 months</time_frame>
    <description>OS was defined as time from date of enrollment to date of death due to any cause. For participants still alive at the time of analysis, OS time was censored on last date that participants were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR（Objective Response Rate）</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>To evaluate the effectiveness of Anlotinib Hydrochloric Capsule Plus Icotinib Hydrochloric Tablet by enhanced CT/MRI scan every two cycles. Objective Response Rate (ORR) is defined as participants who had complete response (CR) or partial response(PR) divided by the total number of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR（Disease Control Rate）</measure>
    <time_frame>each 42 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>To evaluate the effectiveness of Anlotinib Hydrochloric Capsule Plus Icotinib Hydrochloric Tablet by enhanced CT/MRI scan every two cycles. Disease Control Rate (DCR) defined as the percentage of participants with Disease Control best overall response (complete response, partial response or stable disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Until 30 day safety follow-up visit</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Anlotinib Combined With Osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Osimertinib 80mg p.o, qd. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Combined With Osimertinib</intervention_name>
    <description>Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).
Osimertinib：80 mg/tablet， per os (p.o.) daily. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.</description>
    <arm_group_label>Anlotinib Combined With Osimertinib</arm_group_label>
    <other_name>A+T</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed, locally advanced and/or metastatic IIIB,
             IIIC or IV non-squamous NSCLC or recurrent non-squamous NSCLC (according to the 8th
             Edition of the AJCC Staging system).

          2. Non-small cell lung cancer (NSCLC) with an activating EGFR mutation (exon 19 deletion,
             L858R point mutation, or any other mutation known to be associated with EGFR TKI
             sensitivity); presence of an activating EGFR mutation may be documented in tumor
             tissue or by plasma testing.

          3. Locally confirmed T790M mutation determined from biopsy (preferred) or on circulating
             tumour DNA, documented in tissue, plasma or serum after disease progression on the
             most recent first- or second-generation EGFR TK treatment regimen.

          4. 18-75years，ECOG PS：0-2，Life expectancy of more than 3 months，with measurable lesion (
             RECIST1.1).

          5. ≥1 target lesion that has not received radiotherapy in the past 3 months and can be
             accurately measured in at least 1 direction；Previously received radiation therapy, but
             the radiotherapy area must be &lt;25% of the bone marrow area, and radiation therapy must
             have closed for at least≥4 weeks at the time of enrollment.

          6. Main organs function is normal.

          7. Signed and dated informed consent.

          8. The woman patients of childbearing age must agree to take contraceptive methods during
             the research and within another 8 weeks after treatment. Pregnancy test (blood serum
             test or urine) should be done within 7 days before the research and the result should
             be negative.The man patients who must agree to take contraceptive methods during the
             research and within another 8 weeks after treatment.

        Exclusion Criteria:

          1. Squamous cell carcinoma (including adenosquamous carcinoma); Small Cell Lung Cancer
             (including small cell cancer and other kinds of cancer mixed with non-small cell
             cancer)

          2. Non-small cell lung cancer (NSCLC) with an EGFR C797S mutation.

          3. Prior treatment with a third-generation EGFR TKI (i.e. Rociletinib,
             Olmutinib、BPI-15086、BPI-7711、Osimertinib); Prior treatment with agents targeting the
             VEGF pathway, including bevacizumab and Anlotinib.

          4. Treatment with an EGFR TKI (i.e. erlotinib, gefitinib or afatinib) within 8 days or
             approximately 5 x half-life, whichever is longer, of the first dose of study
             treatment；Patients may not be receiving any other investigational agents and may not
             have participated in a study of an investigational agent or using an investigational
             device within five half-lives of the compound or 3 months, whichever is greater

          5. Any unresolved toxicities from prior therapy greater than Common Terminology Criteria
             for Adverse Events (CTCAE) grade 1 at the time of starting study treatment with the
             exception of alopecia and grade 2 platinum-therapy related neuropathy

          6. Any factor that would preclude adequate absorption of Osimertinib and Anlotinib,
             including refractory nausea and vomiting, chronic gastrointestinal diseases, inability
             to swallow the formulated product or previous significant bowel resection

          7. Patients with obvious brain metastases, cancerous meningitis, spinal cord compression,
             or with brain or pia mater disease. (patient with brain metastases who have completed
             treatment 28 days before and the symptoms are stable can be Enrolled, also should have
             no cerebral hemorrhage symptoms confirmed by brain MRI, CT or venography evaluation

          8. Patients who planned to receive systemic anti-tumor therapy within 4 weeks prior to
             allocation or during the course of this study, including cytotoxic therapy, signal
             transduction inhibitors, immunotherapy (or receiving the Mitomycin C 6 weeks prior to
             medication). Extra-field radiotherapy (EF-RT) was performed 4 weeks prior to
             allocation or restricted radiotherapy for assessing tumor lesions within 2 weeks prior
             to allocation

          9. Patients with any severe and/or uncontrolled disease, including:

               1. Inadequately controlled hypertension (HTN) (systolic blood pressure [SBP] &gt; 140
                  mmHg and/or diastolic blood pressure [DBP] &gt; 90 mmHg despite antihypertensive
                  medication)

               2. Mean resting corrected QT interval (Fridericia's correction formula [QTcF]) &gt; 470
                  ms ms obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG
                  machine derived corrected QT (QTc) value; Any clinically important abnormalities
                  in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle
                  branch block, third degree heart block, second degree heart block); Any factors
                  that increase the risk of QTc prolongation or risk of arrhythmic events such as
                  heart failure, hypokalemia, congenital long QT syndrome, family history of long
                  QT syndrome or unexplained sudden death under 40 years of age in first degree
                  relatives or any concomitant medication known to prolong the QT interval;

               3. Active or uncontrollable serious infection (≥CTC AE Level 2 infection)

               4. Liver cirrhosis, decompensated liver disease, active hepatitis or chronic
                  hepatitis need to be treated with antiretroviral therapy

               5. Poor control of diabetes (fasting blood glucose [FBG]&gt; 10 mmol/L)

               6. Urine routine test protein ≥++, and confirmed 24 hours urine protein&gt; 1.0 g

         10. Long-term unhealed wounds or fractures

         11. Evidence of bleeding diathesis or coagulopathy (including clinically significant
             hemoptysis)

         12. Patients with artery/venous thrombotic occurred within 12 months before allocation,
             such as cerebrovascular accident (including temporary ischemic attack), deep vein
             thrombosis and pulmonary embolism

         13. Past medical history of interstitial lung disease, drug-induced interstitial lung
             disease, radiation pneumonitis which required steroid treatment, or any evidence of
             clinically active interstitial lung disease

         14. Patients with a history of psychotropic medicine abuse and cannot quit or have mental
             disorders

         15. Respiratory syndrome (dyspnea≥CTC AE 2), severe pleural effusion, ascites, pericardial
             effusion

         16. History of immunodeficiency, including HIV-positive or other acquired, congenital
             immunodeficiency disease, or history of organ transplantation; active infection
             including hepatitis B (HBV DNA level ≥1000 copies /mL), hepatitis C and human
             immunodeficiency virus (HIV)

         17. Has a history of malignant tumors. Except for patients with cutaneous basal cell
             carcinoma, superficial bladder cancer, cutaneous squamous cell carcinoma or orthotopic
             cervical cancer who have undergone curative treatment and have no disease recurrence
             within 5 years after the start of treatment

         18. History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to AZD9291 (osimertinib) or Anlotinib

         19. Patient was diagnosed with disease which will severely endanger the security of
             patients or influence the completion of this research; Judgment by the investigator
             that should not participate in the study if the patient is unlikely to comply with
             study procedures, restrictions and requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richeng Jiang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hebei Provincial People's Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincal Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.</citation>
    <PMID>27959700</PMID>
  </reference>
  <reference>
    <citation>Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018 Nov 1;4(11):1569-1575. doi: 10.1001/jamaoncol.2018.3039. Erratum in: JAMA Oncol. 2018 Nov 1;4(11):1625.</citation>
    <PMID>30098152</PMID>
  </reference>
  <results_reference>
    <citation>Akamatsu H, Teraoka S, Morita S, Katakami N, Tachihara M, Daga H, Yamamoto N, Nakagawa K. Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). Clin Lung Cancer. 2019 Jul;20(4):e492-e494. doi: 10.1016/j.cllc.2019.03.002. Epub 2019 Mar 19.</citation>
    <PMID>31085043</PMID>
  </results_reference>
  <results_reference>
    <citation>Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8.</citation>
    <PMID>30975627</PMID>
  </results_reference>
  <results_reference>
    <citation>Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014 Oct;15(11):1236-44. doi: 10.1016/S1470-2045(14)70381-X. Epub 2014 Aug 27. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.</citation>
    <PMID>25175099</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 21, 2019</study_first_submitted>
  <study_first_submitted_qc>July 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individul participant data for all primary and secondary outcome measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available within 6 months of study completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external indepentent Review Panel. Requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

